Related references
Note: Only part of the references are listed.Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients
T. Narita et al.
DIABETES OBESITY & METABOLISM (2012)
International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers
Miyako Kishimoto et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Comparing the Efficacy of α-Glucosidase Inhibitors in Suppressing Postprandial Hyperglycemia Using Continuous Glucose Monitoring: A Pilot Study-The MAJOR Study
Daisuke Tsujino et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Single Administration of α-Glucosidase Inhibitors on Endothelial Function and Incretin Secretion in Diabetic Patients With Coronary Artery Disease - Juntendo University Trial: Effects of Miglitol on Endothelial Vascular Reactivity in Type 2 Diabetic Patients With Coronary Heart Disease (J-MACH)
Makoto Hiki et al.
CIRCULATION JOURNAL (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes Understanding and implementing the International Diabetes Federation guidelines
Baptist Gallwitz
DIABETES CARE (2009)
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients
T. Narita et al.
DIABETIC MEDICINE (2009)
Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes
Hiromi Ochiai et al.
ENDOCRINE JOURNAL (2008)
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects
Masayuki Arakawa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus
Hiroki Yokoyama et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients
K Hücking et al.
DIABETIC MEDICINE (2005)
alpha-Glucosidase inhibitors for patients with type 2 diabetes - Results from a cochrane systematic review and meta-analysis
FA van de Laar et al.
DIABETES CARE (2005)
Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes
S Ogawa et al.
DIABETES OBESITY & METABOLISM (2004)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
M Hanefeld et al.
EUROPEAN HEART JOURNAL (2004)
Importance of weight management in Type 2 diabetes: Review with meta-analysis of clinical studies
JW Anderson et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2003)
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics
A Lee et al.
DIABETES OBESITY & METABOLISM (2002)
Share Paper
